Company news

Zentalis Pharmaceuticals, Inc. news in 2026

Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

November 9, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

November 3, 2026

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2026

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

October 23, 2026

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

October 18, 2026

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 18, 2026

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13, 2026

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13, 2026

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

August 6, 2026

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

May 21, 2026

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 12, 2026

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 5, 2026

Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4)

May 4, 2026

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

April 20, 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

April 17, 2026

Zentalis Pharmaceuticals Announces 400mg QD 5: 2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

April 8, 2026

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

March 26, 2026

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 17, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

February 3, 2026

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

January 6, 2026

Decks in 2026